Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
Myocardial infarction (MI) is one of the leading cause s of health loss globally, representing a large proportion of general disability. Anxiety and depression occur in 20-30 percent of patients following MI and have been identified as risk factors for recurrent adverse cardiac event. The purpose of our this study is to develop and evaluate a disease specific cognitive behavioral therapy (C BT) protocol to reduce cardia anxiety, depression, increase physical inactivity and quality of life (Q oL) in patients following MI.
Description: Measure of cardiac anxiety, fear, avoidance and attention. The score ranges between 0 and 72, with a greater score indicating elevated cardiac anxiety.
Measure: Cardiac anxiety questionnaire Time: baselineDescription: Measure of cardiac anxiety, fear, avoidance and attention. The score ranges between 0 and 72, with a greater score indicating elevated cardiac anxiety.
Measure: Cardiac anxiety questionnaire Time: 2 months from baselineDescription: Measure of cardiac anxiety, fear, avoidance and attention. The score ranges between 0 and 72, with a greater score indicating elevated cardiac anxiety.
Measure: Cardiac anxiety questionnaire Time: 8 months from baselineDescription: General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life.
Measure: 12-Item Short-Form Health Survey (SF-12) Time: BaselineDescription: General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life.
Measure: 12-Item Short-Form Health Survey (SF-12) Time: 2 months from baselineDescription: General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life.
Measure: 12-Item Short-Form Health Survey (SF-12) Time: 8 months from baselineDescription: Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations.
Measure: Body Sensation Questionnaire Time: BaselineDescription: Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations.
Measure: Body Sensation Questionnaire Time: 2 months from baselineDescription: Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations.
Measure: Body Sensation Questionnaire Time: 8 months from baselineDescription: Measure of depression, score ranging 0 to 27 with a higher score indicating higher level of depression.
Measure: Patient Health Questionnaire-9 Time: BaselineDescription: Measure of depression, score ranging 0 to 27 with a higher score indicating higher level of depression.
Measure: Patient Health Questionnaire-9 Time: 2 months from BaselineDescription: Measure of depression, score ranging 0 to 27 with a higher score indicating higher level of depression.
Measure: Patient Health Questionnaire-9 Time: 8 months from BaselineDescription: General anxiety, score ranging from 0-21, with a higher score indicating more anxiety and worry.
Measure: Generalized Anxiety Disorder 7-item Time: BaselineDescription: General anxiety, score ranging from 0-21, with a higher score indicating more anxiety and worry.
Measure: Generalized Anxiety Disorder 7-item Time: 2 months from baselineDescription: General anxiety, score ranging from 0-21, with a higher score indicating more anxiety and worry.
Measure: Generalized Anxiety Disorder 7-item Time: 8 months from baselineDescription: Level of physical activity. The participant rate numbers of time per week that they engage in physical activity. The numb ers are the categorized in to low, moderate, and high levels of physical activity.
Measure: The Godin Leisure-time Exercise Time: BaselineDescription: Level of physical activity. The participant rate numbers of time per week that they engage in physical activity. The numb ers are the categorized in to low, moderate, and high levels of physical activity.
Measure: The Godin Leisure-time Exercise Time: 2 months from BaselineDescription: Level of physical activity. The participant rate numbers of time per week that they engage in physical activity. The numb ers are the categorized in to low, moderate, and high levels of physical activity.
Measure: The Godin Leisure-time Exercise Time: 8 months from BaselineDescription: Fear of physical activity. The total score varies between 17 and 68, with higher values indicating more severe kinesiophobia.
Measure: Tampas Scale for Kinesophobia-Heart version Time: BaselineDescription: Fear of physical activity. The total score varies between 17 and 68, with higher values indicating more severe kinesiophobia.
Measure: Tampas Scale for Kinesophobia-Heart version Time: 2 months from BaselineDescription: Fear of physical activity. The total score varies between 17 and 68, with higher values indicating more severe kinesiophobia.
Measure: Tampas Scale for Kinesophobia-Heart version Time: 8 months form BaselineDescription: Treatment satisfaction, score ranging from 0 to 32, with a higher score indication more satisfaction with the treatment.
Measure: Client satisfaction Questionnaire Time: 2 months from BaselineDescription: Potential adverse reactions to the treatment. Participants will be asked to report and rate the short- and long term discomfort of the adverse event on a scale from 0 ('did not affect me at all') and 3 ('affected me very negatively').
Measure: Adverse events Time: 2 months from baselineDescription: Potential adverse reactions to the treatment. Participants will be asked to report and rate the short- and long term discomfort of the adverse event on a scale from 0 ('did not affect me at all') and 3 ('affected me very negatively').
Measure: Adverse events Time: 8 months from baselineAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports